Yaping Z Sun

US Patent:

8022182, Sep 20, 2011

Filed:

Feb 11, 2010

Appl. No.:

12/704190

Inventors:

Christine Ambrose - Reading MA, US
Jeffrey Thompson - Stoneham MA, US
Yen-Ming Hsu - Lexington MA, US
Dingyi Wen - Waltham MA, US
Yaping Sun - Lexington MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

C07K 14/435
C07K 14/705
C07K 14/71
C07K 14/715
A61K 38/17
A61K 38/18

US Classification:

530350, 530300, 514 11, 514 76, 514 79

Abstract:

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.

US Patent:

8303958, Nov 6, 2012

Filed:

Aug 19, 2011

Appl. No.:

13/213826

Inventors:

Christine Ambrose - Reading MA, US
Jeffrey Thompson - Stoneham MA, US
Yen-Ming Hsu - Lexington MA, US
Dingyi Wen - Waltham MA, US
Yaping Sun - Lexington MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 38/00
A61K 38/17
A61K 38/18
C07K 14/435
C07K 14/705
C07K 14/71
C07K 14/715

US Classification:

4241841, 514 11, 514 79, 514 166, 514 192, 530300, 530350

Abstract:

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.

US Patent:

20020081664, Jun 27, 2002

Filed:

Oct 11, 2001

Appl. No.:

09/977034

Inventors:

Kin-Ming Lo - Lexington MA, US
Yaping Sun - Arlington MA, US
Stephen Gillies - Carlisle MA, US

International Classification:

C12P021/02
C07H021/04
C12N005/06
C07K016/46

US Classification:

435/069500, 435/325000, 435/320100, 536/023530, 530/351000, 530/391100

Abstract:

Disclosed are nucleic acid sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc-Interferon-alpha fusion protein. The nucleic acid sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc-Interferon-alpha fusion proteins that can be produced by expression of such nucleic acid sequences. Also disclosed are methods of using such nucleic acid sequences and/or fusion proteins for treating conditions, for example, hepatitis, which are alleviated by the administration of interferon-alpha.

US Patent:

20050042729, Feb 24, 2005

Filed:

Sep 29, 2004

Appl. No.:

10/953259

Inventors:

Kin-Ming Lo - Lexington MA, US
Yaping Sun - Norwood MA, US
Stephen Gillies - Carlisle MA, US

Assignee:

EMD Lexigen Research Center Corp. - Billerica MA

International Classification:

C07H021/04
C07K016/18

US Classification:

435069100, 435320100, 435328000, 530387300, 536023530

Abstract:

Disclosed are nucleic acid sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc-Interferon-alpha fusion protein. The nucleic acid sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc-Interferon-alpha fusion proteins that can be produced by expression of such nucleic acid sequences. Also disclosed are methods of using such nucleic acid sequences and/or fusion proteins for treating conditions, for example, hepatitis, which are alleviated by the administration of interferon-alpha.

US Patent:

20060234917, Oct 19, 2006

Filed:

Mar 26, 2004

Appl. No.:

10/550961

Inventors:

Christine Ambrose - Reading MA, US
Jeffrey Thompson - Stoneham MA, US
Yen-Ming Hsu - Lexington MA, US
Dingyi Wen - Waltham MA, US
Yaping Sun - Lexington MA, US

International Classification:

A61K 38/17
C07K 14/705
C07H 21/04
C12P 21/06

US Classification:

514008000, 530350000, 530395000, 435069100, 435320100, 435325000, 536023500

Abstract:

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.

US Patent:

20130177558, Jul 11, 2013

Filed:

Oct 4, 2012

Appl. No.:

13/645104

Inventors:

Biogen Idec MA Inc. - Cambridge MA, US
Jeffrey Thompson - Stoneham MA, US
Yen-Ming Hsu - Lexington MA, US
Dingyi Wen - Waltham MA, US
Yaping Sun - Lexington MA, US

Assignee:

BIOGEN IDEC MA INC. - Cambridge MA

International Classification:

C07K 14/715

US Classification:

4241341, 514 193, 514 196

Abstract:

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.

US Patent:

20150023961, Jan 22, 2015

Filed:

Jul 28, 2014

Appl. No.:

14/444139

Inventors:

Christine Ambrose - Reading MA, US
Jeffrey Thompson - Stoneham MA, US
Yen-Ming Hsu - Lexington MA, US
Dingyi Wen - Waltham MA, US
Yaping Sun - Lexington MA, US

Assignee:

BIOGEN IDEC MA INC. - Cambridge MA

International Classification:

C07K 14/715
C07K 16/28

US Classification:

4241341, 4241851

Abstract:

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.